Search Result

Isoforms Recommended:	MAP4K1/HPK1

Results for "

HPK1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (1) IFNAR (1) Interleukin Related (1) MAP4K (47) PROTACs (3) Src (1)
By Research Areas:	Cancer (42) Infection (1) Inflammation/Immunology (19)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148847

HPK1-IN-32

MAP4K Cancer

HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC₅₀ of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases ^[1].

HPK1-IN-32	MAP4K	Cancer
HPK1-IN-32 is a potent and selective *HPK1* inhibitor with an IC₅₀ of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases ^[1].

HY-144093

HPK1-IN-26	MAP4K	Infection
HPK1-IN-26 is a *HPK1* and GLK inhibitor extracted from patent WO2021254118A1 compound 1. HPK1-IN-26 can be used for the research of animal pathogen infection ^[1].

HY-153553

HPK1 antagonist-1

MAP4K Others

HPK1 antagonist-1 (I-792) is an Hpk1 antagonist that can be used in the study of cancer and immune disease ^[1].

HPK1 antagonist-1	MAP4K	Others
HPK1 antagonist-1 (I-792) is an *Hpk1* antagonist that can be used in the study of cancer and immune disease ^[1].

HY-156508

HPK1-IN-37	MAP4K	Cancer
HPK1-IN-37 (compound A85) is an inhibitor of HPK1 (IC₅₀=3.7 nM). HPK1-IN-37 can be used for research in HPK1 related disorders or diseases including cancers ^[1].

HY-160217

HPK1-IN-41

MAP4K Cancer

HPK1-IN-41 (compound Z389) is an inhibitor of HPK1 with an IC₅₀ value of 0.21 nM ^[1].

HPK1-IN-41	MAP4K	Cancer
HPK1-IN-41 (compound Z389) is an inhibitor of *HPK1* with an IC₅₀ value of 0.21 nM ^[1].

HY-152257

HPK1-IN-31	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-31 (compound 5i) is an orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunoresearch ^[1].

HY-144091

HPK1-IN-24	MAP4K	Cancer
HPK1-IN-24 (example 51) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a K_i of 100 nM. HPK1-IN-24 has the potential for cancer research ^[1].

HY-145109

HPK1-IN-20

MAP4K Inflammation/Immunology Cancer

HPK1-IN-19 is a hematopoietic progenitor kinase 1 (HPK1) inhibitor extracted from patent WO2020235902A1 compound 106 ^[1].

HPK1-IN-20	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-19 is a hematopoietic progenitor kinase 1 (HPK1) inhibitor extracted from patent WO2020235902A1 compound 106 ^[1].

HY-144092

HPK1-IN-25	MAP4K	Cancer
HPK1-IN-25 (example 94) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a enzymatic activity IC₅₀ of 129 nM. HPK1-IN-25 has the potential for cancer research ^[1].

HY-145107

HPK1-IN-19

MAP4K Inflammation/Immunology Cancer

HPK1-IN-19 is a hematopoietic progenitor kinase 1 (HPK1) inhibitor extracted from patent WO2018102366A1 compound I-47 ^[1].

HPK1-IN-19	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-19 is a hematopoietic progenitor kinase 1 (HPK1) inhibitor extracted from patent WO2018102366A1 compound I-47 ^[1].

HY-149206

HPK1-IN-33	MAP4K	Cancer
HPK1-IN-33 (compound 21) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a K_i value of 1.7 nM. HPK1-IN-33 inhibits the produce of IL-2 with EC₅₀s of 286, >10000 nM in Jurkat WT and Jurkat HPK1 KO cells, respectively ^[1].

HY-145036

HPK1-IN-10	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-10 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) ^[1].

HY-145037

HPK1-IN-11	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-11 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2) ^[1].

HY-145038

HPK1-IN-12	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-12 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) ^[1].

HY-145039

HPK1-IN-13	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-13 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) ^[1].

HY-145040

HPK1-IN-14	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-14 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) ^[1].

HY-145035

HPK1-IN-9	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-9 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) ^[1].

HY-143869

HPK1-IN-28	MAP4K	Cancer
HPK1-IN-28 is a potent inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1*-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) ^[1].

HY-143870

HPK1-IN-29	MAP4K	Cancer
HPK1-IN-29 is a potent inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1*-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) ^[1].

HY-145041

HPK1-IN-15	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-15 is a potent and selective inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-15 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1* activity such as cancer (extracted from patent WO2018049200A1, compound 50) ^[1].

HY-145042

HPK1-IN-16	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-16 is a potent and selective inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-16 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1* activity such as cancer (extracted from patent WO2019051199A1, compound 39) ^[1].

HY-145044

HPK1-IN-17	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-17 is a potent and selective inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-17 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1* activity such as cancer (extracted from patent WO2019238067A1, compound 73) ^[1].

HY-145045

HPK1-IN-18	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-18 is a potent and selective inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-18 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1* activity such as cancer (extracted from patent WO2019238067A1, compound 1) ^[1].

HY-138568

HPK1-IN-3	MAP4K	Inflammation/Immunology
HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC₅₀ of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC₅₀ of 108 nM in human peripheral blood mononuclear cells (PBMCs) ^[1].

HY-143868

HPK1-IN-27	MAP4K	Cancer
HPK1-IN-27 is a potent inhibitor of *HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1*-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) ^[1].

HY-143871

HPK1-IN-30	MAP4K	Cancer
HPK1-IN-30 is a potent inhibitor of *HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1*-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) ^[1].

HY-132150A

HPK1-IN-2 dihydrochloride	MAP4K FLT3 Src	Cancer
HPK1-IN-2 dihydrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC₅₀<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 µΜ<IC₅₀<0.5 µΜ) and Flt3 (IC₅₀<0.05 µΜ) kinase activities ^[1].

HY-160218

HPK1-IN-42

MAP4K Cancer

HPK1-IN-42 (compound 185) ia a HPK1 inhibitor with the IC₅₀ 50 of 0.24 nM ^[1].

HPK1-IN-42	MAP4K	Cancer
HPK1-IN-42 (compound 185) ia a *HPK1* inhibitor with the IC₅₀ 50 of 0.24 nM ^[1].

HY-149773S

HPK1-IN-40-d2	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-40 (compound 49) is a potent and selective *HPK1* inhibitor with an IC₅₀ of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity ^[1].

HY-149520

HPK1-IN-39	MAP4K	Cancer
HPK1-IN-39 (Compound 10n) is a selective *HPK1* Inhibitor (IC₅₀: 29 nM). HPK1-IN-39 inhibits the phosphorylation of SLP76. HPK1-IN-39 can be used for research of cancer immunotherapy ^[1].

HY-144073

HPK1-IN-21

MAP4K Cancer

HPK1-IN-21 is a potent inhibitor of HPK1 kinase inhibitor (Ki=0.8 nM). HPK1-IN-21 also has orally active ^[1].
HY-156509

HPK1-IN-38

MAP4K Others

HPK1-IN-38 (compound 15) is a MAP4K1/HPK1 inhibitor，can be used for HPK1 related disorders research ^[1].
HY-132926

HPK1-IN-8

MAP4K Cancer

HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1.

HPK1-IN-21	MAP4K	Cancer
HPK1-IN-21 is a potent inhibitor of *HPK1* kinase inhibitor (Ki=0.8 nM). HPK1-IN-21 also has orally active ^[1].

HPK1-IN-38	MAP4K	Others
HPK1-IN-38 (compound 15) is a *MAP4K1/HPK1* inhibitor，can be used for HPK1 related disorders research ^[1].

HPK1-IN-8	MAP4K	Cancer
HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length *HPK1*.

HY-149232

HPK1-IN-35	MAP4K	Cancer
HPK1-IN-35 is a potent and selective *HPK1* inhibitor with an IC₅₀ value of 3.5 nM. HPK1-IN-35 decreases the expression of p-SLP76 and promotes IL-2 secretion ^[1].

HY-153448

HPK1-IN-36

MAP4K Cancer

HPK1-IN-36 (compound 2) is a potent HPK1 inhibitor with an IC₅₀ value of 0.5 nM ^[1].

HPK1-IN-36	MAP4K	Cancer
HPK1-IN-36 (compound 2) is a potent *HPK1* inhibitor with an IC₅₀ value of 0.5 nM ^[1].

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a *HPK1* kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research ^[1].

HY-138569

HPK1-IN-4

MAP4K Cancer

HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC₅₀ of 0.061 nM) as preclinical immunoresearch tool compound ^[1].

HPK1-IN-4	MAP4K	Cancer
HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC₅₀ of 0.061 nM) as preclinical immunoresearch tool compound ^[1].

HY-153362

HPK1-IN-34	MAP4K	Cancer
HPK1-IN-34 (Compound 143) is a Hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ of <100 nM ^[1]. HPK1-IN-34 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-138742

HPK1-IN-7	MAP4K	Cancer
HPK1-IN-7 is a potent, orally active *HPK1* (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC₅₀=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 ^[1].

HY-144088

ZYF0033 HPK1-IN-22	MAP4K	Inflammation/Immunology Cancer
ZYF0033 is effective in inhibiting hematopoietic progenitor cells *HPK1, basically inhibiting MBP protein oxidation IC₅₀* 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a ^{+ CD8 ⁺ T Cells, PD-1 ⁺CD8 ⁺ T Cells, TIM-3 ⁺CD8 ⁺ T Cells LAG3< sup>+}CD8 ⁺ T Cellular immersion decreases.

HY-163372

*PROTAC HPK1* Degrader-1**	MAP4K PROTACs	Cancer
PROTAC HPK1 Degrader-1 (Compound B1) is a potent *HPK1* degrader with DC₅₀ value of 1.8 nM. PROTAC HPK1 Degrader-1 inhibits phosphorylation of the SLP76 protein with IC₅₀ value of 496.1 nM. PROTAC HPK1 Degrader-1 is a bona fide *HPK1-PROTAC* degrader, which provided a potential tool for further HPK1 investigation in TCR signaling ^[1].

HY-146231

SS47	PROTACs MAP4K	Inflammation/Immunology Cancer
SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy ^[1].

HY-146231A

SS47 TFA	MAP4K PROTACs	Inflammation/Immunology Cancer
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies ^[1]. SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135892

GNE-1858 1 Publications Verification	MAP4K	Inflammation/Immunology
GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor, with IC₅₀s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively ^[1].

HY-157149

DS21150768

MAP4K Cancer

DS21150768 is a potent, orally active HPK1 inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects ^[1].
HY-149056

GNE-6893

MAP4K Cancer

GNE-6893 is a potent and orally active HPK1 inhibitor. GNE-6893 can be used in research of cancer ^[1].

DS21150768	MAP4K	Cancer
DS21150768 is a potent, orally active *HPK1* inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects ^[1].

GNE-6893	MAP4K	Cancer
GNE-6893 is a potent and orally active *HPK1* inhibitor. GNE-6893 can be used in research of cancer ^[1].

HY-157838

HMC-B17	MAP4K	Cancer
HMC-B17 is a selective, orally bioavailable HPK1 inhibitor (IC₅₀ = 1.39 nM) that potentiates anti-PD-L1 efficacy. HMC-B17 potently enhances the IL-2 secretion in Jurkat cells (EC₅₀ = 11.56 nM). HMC-B17 can be used for the research of cancer ^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: